Yizhou Zhao

Yizhou Zhao

Auto-generated profile, based on publicly available information

Yizhou Zhao

Department of Radiation Oncology, BC Cancer Surrey, 13750 96 Ave, Surrey, BC, V3V 1Z2, Canada.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Medical Dosimetry
Verified
Journal Article
Closed access
YZYizhou Zhao
Yizhou Zhao
KMKathryn Moran
Kathryn Moran
MYMammo Yewondwossen
Mammo Yewondwossen
JAJames Allan
James Allan
SCScott Clarke
Scott Clarke
JRJames L. Robar
James L. Robar

27 February 2020 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
YZYizhou Zhao
Yizhou Zhao
EKEman Khawandanh
Eman Khawandanh
STSteven Thomas
Steven Thomas
SZSusan Zhang
Susan Zhang
EDEmma M. Dunne
Emma M. Dunne
DSDevin Schellenberg
Devin Schellenberg
Background: For stereotactic body radiotherapy (SBRT) to central (C) and ultracentral (UC) lung tumors, our provincial practice has been to prioritize organs at risk (OARs) constraints by compromising target volume coverage if needed. The objectives are to report the treatment’s efficacy and safety. Methods: We conducted a retrospective analysis of all provincial patients who underwent SBRT at 60Gy in 8 fractions to C and UC lung tumors, from 2013 to 2017. Results: Ninety-eight lesions were treated, 57 (58.2%) C and 41 (41.8%) UC. The median follow-up was 22.9 months (range 2.5–64.8 months). The 1- and 3-year local control (LC) was 97.8 and 84.5% respectively, with no differences between C and UC groups (p = 0.662). Fifty-three (54.1%) cases had optimal dose coverage (V60Gy ITV&PTV > 95%), 29 (29.6%) had compromised PTV coverage (V60Gy ITV > 95%/PTV < 95%), and 16 (16.3%) had both compromised ITV and PTV coverage (V60Gy ITV&PTV < 95%). No significant difference in LC was detected at 2 years between the 3 groups (95.6, 91.8 and 90.9%, p = 0.717). There were 3 episodes of grade 3 toxicity in the C group (2 dyspnea, 1 pneumonitis) and 2 in the UC group (1 dyspnea, 1 hemoptysis). There were no gr4/5 toxicities. On multivariable Cox regression analysis, ITV size was found to be a predictor for LC (p = 0.001). Conclusions: SBRT at 60Gy in 8 fractions achieves high rates of LC with low risks of significant toxicities, even if target volume coverage is reduced to meet OARs constraints.

1 February 2019 in Current Problems in Cancer
Verified
Journal Article
Closed access
YZYizhou Zhao
Yizhou Zhao
MCMathieu Castonguay
Mathieu Castonguay
DWDerek Wilke
Derek Wilke
ZXZhaolin Xu
Zhaolin Xu
MPMadelaine Plourde
Madelaine Plourde
DBDavid Bowes
David Bowes

1 December 2018 in Current Oncology
Verified
Journal Article
Open access
SLS. L. Liu
S. L. Liu
POP. O’bRien
P. O’bRien
YZY. Zhao
Y. Zhao
WHW. M. Hopman
W. M. Hopman
NLN. Lamond
N. Lamond
RRRavi Ramjeesingh
Ravi Ramjeesingh
Background Little is known about the benefits of adjuvant chemotherapy (adj) in the older population with locally advanced rectal cancer (larc). We evaluated use of adj, survival outcomes, and adj-related toxicity in older patients with larc. Methods Our retrospective review included 286 patients with larc (stages ii and iii) diagnosed between January 2010 and December 2013 in Nova Scotia who underwent curative-intent surgery. Baseline patient, tumour, and treatment characteristics were collected. The survival analysis used the Kaplan–Meier method and Cox regression statistics. Results Of 286 identified patients, 152 were 65 years of age or older, and 92 were 70 years of age or older. Median follow-up was 46 months, and 163 patients (57%) received neoadjuvant chemoradiation. Although adj was given to 81% of patients (n = 109) less than 65 years of age, only 29% patients (n = 27) 70 years of age and older received adj. Kaplan–Meier analysis suggested a potential survival advantage for adj regardless of age. In multivariate Cox regression analysis, Eastern Cooperative Oncology Group performance status, T stage, and adj were significant predictors of overall survival (p < 0.04); age was not. Similarly, N stage, neoadjuvant chemoradiation, and adj were significant predictors of disease-free survival (p < 0.01). Poor Eastern Cooperative Oncology Group performance status was the most common cause of adj omission. In patients 70 years of age and older, grade 1 or greater chemotherapy-related toxicities were experienced significantly more often by those treated with adj (85% vs. 68% for those not treated with adj, p < 0.05). Conclusions Regardless of age, patients with larc seem to experience a survival benefit with adj. However, older patients are less likely to receive adj, and when they do, they experience more chemotherapy-related toxicities.